(Q51468997)

English

Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.

scientific article published in July 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

insulin therapy

1 reference

based on heuristic

inferred from title

author name string

Berhanu P

1

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

Perez A

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

Yu S

3

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

publication date

1 July 2007

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

9

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

4

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

512-520

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Thiazolidinediones

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Peroxisome proliferator-activated receptor-γ agonists in atherosclerosis: current evidence and future directions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Lipids and lipoproteins in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Hypoglycemia in diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Combined thiazolidinedione-insulin therapy: should we be concerned about safety?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00633.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2006.00633.X

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/17587394

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51468997&oldid=1562171171"